{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:45Z","timestamp":1793643345415,"version":"4.5.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Along with COVID\u201019 pandemic, India has faced an outbreak of COVID\u201019\u2013associated mucormycosis (CAM). Due to restricted availability of amphotericin B during this outbreak, clinicians were forced to use posaconazole or isavuconazole preparations as first\u2010line or alternate therapy in many patients. We planned an early monitoring of posaconazole trough level while using delayed release (DR) tablet as first\u2010line or alternate therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Primary objective of the study was to determine percentage of patients achieving arbitrarily decided therapeutic posaconazole levels (\u22651.2\u00a0\u03bcg\/ml) after using standard dosages of posaconazole. Secondary objective was to identify potential factors associated with sub\u2010therapeutic posaconazole levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed retrospective chart review of the hospitalised patients, who received posaconazole DR tablet as first\u2010line or alternate therapy to treat CAM during outbreak period (March 1 to May 31, 2021). High\u2010performance liquid chromatographic (HPLC) method was used to measure trough level of posaconazole.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Posaconazole serum levels of 29 patients were analysed, who received posaconazole DR tablet. Majority (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a023) were male with the median (range) age 53 (24\u201386) years. The mean (SD) posaconazole level was 1.66 (0.76)\u00a0\u03bcg\/ml. Sub\u2010therapeutic posaconazole trough level was observed in 7 (24.1%) patients. Relatively younger patients were associated with lower posaconazole level (\n                      <jats:italic>p\u00a0=<\/jats:italic>\n                      \u00a0.046). Except two patients, all the patients tolerated posaconazole well.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The study supports the posaconazole trough level measurement on day 4 while using posaconazole DR tablet as first\u2010line or alternate therapy to treat mucormycosis during limited supply of amphotericin B.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/myc.13420","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:34:42Z","timestamp":1640414082000},"page":"312-316","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID\u201019\u2013associated mucormycosis in a real\u2010life setting"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-2460","authenticated-orcid":false,"given":"Atul","family":"Patel","sequence":"first","affiliation":[{"name":"Infectious Diseases Department Sterling Hospital Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Patel","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Sterling Hospital Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Microbiology Sterling Hospital Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinjal","family":"Shah","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department Sterling Hospital Ahmedabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-3807","authenticated-orcid":false,"given":"Arunaloke","family":"Chakrabarti","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology Postgraduate Institute of Medical Education &amp; Research Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Mucormycosis Black Fungus","author":"Governmentstats.com","year":"2021"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00222-12"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.826989"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-12"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05900-11"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12339"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00389-16"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00768-12"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2709.210934"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13028"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02655-17"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.126-133.2006"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz344"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.13420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.13420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T09:05:55Z","timestamp":1693127155000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.13420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/myc.13420"],"URL":"https:\/\/doi.org\/10.1111\/myc.13420","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"2021-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}